🇺🇸 FDA

Intelligence · Clinical Pipeline

Regeneron UK Pipeline

All ClinicalTrials.gov programs at Regeneron UK — phase, modality, and trial IDs.

Programs
176

Quick answer

Regeneron UK has 176 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. R475

    Regeneron UK Limited

    Thermal Injury Pain

    phase 2 small molecule terminated

    1 trial

  2. REGN1033 (SAR391786)

    Regeneron UK Limited

    Sarcopenia

    phase 2 small molecule completed

    1 trial

  3. REGN10597

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  4. REGN10933+REGN10987 combination therapy

    Regeneron UK Limited

    COVID-19

    phase 2 small molecule completed

    2 trials

  5. REGN13335

    Regeneron UK Limited

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  6. REGN14256

    Regeneron UK Limited

    SARS-CoV-2

    phase 2 small molecule terminated

    1 trial

  7. REGN1500 250 mg SC/15 mg/kg IV/450 mg SC

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  8. REGN15505

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  9. REGN1908-1909

    Regeneron UK Limited

    Cat Allergy

    phase 2 small molecule completed

    1 trial

  10. REGN2176-3

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 2 small molecule terminated

    1 trial

  11. REGN2477

    Regeneron UK Limited

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule completed

    1 trial

  12. REGN2477+REGN1033

    Regeneron UK Limited

    Sporadic Inclusion Body Myositis

    phase 2 small molecule terminated

    1 trial

  13. REGN2810

    Regeneron UK Limited

    Prostate Cancer Metastatic

    phase 2 small molecule active

    1 trial

  14. REGN3500

    Regeneron UK Limited

    Atopic Dermatitis

    phase 2 small molecule terminated

    2 trials

  15. REGN3918

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

  16. REGN4336

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  17. REGN4461

    Regeneron UK Limited

    Familial Partial Lipodystrophy

    phase 2 small molecule terminated

    1 trial

  18. REGN475

    Regeneron UK Limited

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  19. REGN475

    Regeneron UK Limited

    Osteoarthritis

    phase 2 mab terminated

    1 trial

  20. REGN475

    Regeneron UK Limited

    Sciatica

    phase 2 small molecule completed

    1 trial

  21. REGN475/SAR164877

    Regeneron UK Limited

    Back Pain

    phase 2 small molecule terminated

    1 trial

  22. REGN475/SAR164877

    Regeneron UK Limited

    Abdominal Pain Upper

    phase 2 small molecule terminated

    1 trial

  23. REGN5069

    Regeneron UK Limited

    Osteoarthritis of the Knee

    phase 2 small molecule terminated

    1 trial

  24. REGN5093

    Regeneron UK Limited

    NSCLC

    phase 2 small molecule active

    1 trial

  25. REGN5381

    Regeneron UK Limited

    Uncontrolled Hypertension

    phase 2 small molecule terminated

    1 trial

  26. REGN5381

    Regeneron UK Limited

    Heart Failure

    phase 2 small molecule terminated

    2 trials

  27. REGN5459

    Regeneron UK Limited

    Relapsed Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  28. REGN5668

    Regeneron UK Limited

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  29. REGN5678

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  30. REGN7041

    Regeneron UK Limited

    Active Noninfectious Uveitis Affecting the Posterior Segment

    phase 2 small molecule active

    1 trial

  31. REGN7075

    Regeneron UK Limited

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  32. REGN7508

    Regeneron UK Limited

    Venous Thromboembolism

    phase 2 small molecule completed

    1 trial

  33. REGN7544

    Regeneron UK Limited

    Sepsis-Induced Hypotension

    phase 2 small molecule completed

    1 trial

  34. REGN7544

    Regeneron UK Limited

    Postural Orthostatic Tachycardia Syndrome (POTS)

    phase 2 small molecule active

    1 trial

  35. REGN7999

    Regeneron UK Limited

    Non-Transfusion Dependent Beta-Thalassemia (NTDT)

    phase 2 small molecule active

    1 trial

  36. REGN846

    Regeneron UK Limited

    Pruritus

    phase 2 small molecule terminated

    1 trial

  37. REGN910-3

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial

  38. REGN910-3

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 2 small molecule completed

    2 trials

  39. REGN9933

    Regeneron UK Limited

    Venous Thromboembolism

    phase 2 small molecule completed

    2 trials

  40. REGV131

    Regeneron UK Limited

    Hemophilia B

    phase 2 small molecule active

    1 trial

  41. Rilonacept

    Regeneron UK Limited

    Scleroderma

    phase 2 small molecule completed

    1 trial

  42. Rilonacept

    Regeneron UK Limited

    Cold Contact Urticaria

    phase 2 small molecule completed

    1 trial

  43. Rilonacept

    Regeneron UK Limited

    Chronic Kidney Disease

    phase 2 small molecule terminated

    1 trial

  44. S095018

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  45. SAR440340

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  46. SAR440340

    Regeneron UK Limited

    Asthma

    phase 2 small molecule completed

    1 trial

  47. SAR444881

    Regeneron UK Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  48. SDREGN2810

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many pipeline programs does Regeneron UK have?

176 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.